<DOC>
	<DOCNO>NCT00000671</DOCNO>
	<brief_summary>To compare effectiveness toxicity didanosine ( ddI ) zidovudine ( AZT ) patient AIDS advance AIDS-related complex ( ARC ) tolerate AZT therapy 12 month longer . Per amendment , asymptomatic patient CD4 count less 200 cells/mm3 eligible . AZT effective reduce mortality patient AIDS receive drug first episode Pneumocystis carinii pneumonia ( PCP ) patient advanced ARC . However , AZT therapy associate significant toxicity . In addition , effectiveness AZT appear decrease second third year therapy . For reason , development alternative therapy would least effective less toxic great importance . The drug ddI antiviral agent inhibits replication HIV le apparent toxicity AZT . Studies indicate ddI remain active body least 12 hour ; thus benefit ddI might achieve low frequency drug administration .</brief_summary>
	<brief_title>A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine ( ddI ) ( BMY-40900 ) Zidovudine Therapy Patients With HIV Infection Who Have Been Long Term Zidovudine Treatment</brief_title>
	<detailed_description>AZT effective reduce mortality patient AIDS receive drug first episode Pneumocystis carinii pneumonia ( PCP ) patient advanced ARC . However , AZT therapy associate significant toxicity . In addition , effectiveness AZT appear decrease second third year therapy . For reason , development alternative therapy would least effective less toxic great importance . The drug ddI antiviral agent inhibits replication HIV le apparent toxicity AZT . Studies indicate ddI remain active body least 12 hour ; thus benefit ddI might achieve low frequency drug administration . Two dose level ddI , adjust depend patient 's weight study entry , compare variable dosage regimen AZT ( dose patient tolerate time study entry ) . Randomization stratify baseline CD4 cell count ( less 100 100-300 ) Medical Center . This study continue least 12 month entry first subject . Patients randomized AZT receive orally . All patient randomize AZT also receive ddI placebo 12 hour interval . Patients randomized ddI receive AZT placebo .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Aerosolized pentamidine ( 300 mg every 4 week ) . Allowed : Chronic suppressive treatment toxoplasmosis , Pneumocystis carinii pneumonia ( PCP ) , cryptococcal meningitis , herpes simplex virus infection . Ganciclovir patient develop cytomegalovirus ( CMV ) infection study . Erythropoietin patient relevant treatment IND . Treatment opportunistic infection sulfonamidecontaining regimen . Aspirin , acetaminophen , nonsteroidal antiinflammatory agent discourage , permit short period time possible . Chronic use trimethoprim sulfamethoxazole sulfonamide preparation encourage study . Patients must : Have diagnosis AIDS advance AIDS relate complex ( ARC ) . Have receive AZT therapy least 12 month , minimal daily dose 500 mg/day 60 day AZT therapy within 12 month period ; medical record documentation AZT dosing must provide . Provide inform consent ( guardian appropriate ) . Be available followup least 6 month . Have inclusion laboratory value within approximately 14 day initiate therapy ( except CD4 cell count ) . Patients whose AIDSdefining condition Kaposi 's sarcoma alone must CD4 cell count &lt; 300 cells/mm3 . Allowed : Positive blood culture Mycobacterium avium Cytomegalovirus . Prior history toxoplasmosis , Herpes simplex , Cryptococcus , Pneumocystis carinii pneumonia ( PCP ) require chronic suppressive therapy . Occasional premature atrial ventricular contraction . Prior Medication : Required : Zidovudine ( AZT ) therapy least 12 month , minimal daily dose 500 mg/day , 60 day AZT therapy within 12month period ( documentation AZT dosing must provide ) . Allowed : Intralesional agent . Exclusion Criteria Coexisting Condition : Patients follow excluded : Psychological emotional problem sufficient , investigator 's opinion , prevent adequate compliance study therapy . AIDSdementia complex = &gt; stage 2 . Active AIDS defining opportunistic infection specifically allow . Intractable diarrhea . Grade 2 neuropathy , base Neuropathy Targeted Symptom Questionnaire , moderate abnormality indicative peripheral neuropathy , particularly impaired sensation sharp pain , light touch , vibration low extremity , distal extremity weakness , distal extremity hyperreflexia . Prior history acute pancreatitis within past 2 year chronic pancreatitis . History seizure within past 2 year currently require anticonvulsant control . History past current heart disease . Malignancy likely investigator 's opinion require cytotoxic chemotherapy expect course trial . Life expectancy &lt; 3 month . Concurrent Medication : Excluded : Isoniazid ( INH ) . Neurotoxic drug . Oral acidify agent . Patients follow excluded : Psychological emotional problem sufficient , investigator 's opinion , prevent adequate compliance study therapy . AIDSdementia complex = &gt; stage 2 . Active AIDS defining opportunistic infection specifically allow . Intractable diarrhea . Prior history acute pancreatitis within past 2 year chronic pancreatitis . History seizure within past 2 year currently require anticonvulsant control . History past current heart disease . Malignancy likely investigator 's opinion require cytotoxic chemotherapy expect course trial . Life expectancy = &lt; 3 month . Previous participation study ddI , ddC d4T . Prior Medication : Excluded : Ganciclovir ( DHPG ) . Excluded within 1 month study entry : ddI antiretroviral drug investigational antiHIV agent except zidovudine ( AZT ) . Interferons . Immunomodulating drug . Cytotoxic agent specifically allow . Neurotoxic drug . Excluded within 3 month study entry : Ribavirin . Prior Treatment : Excluded within 14 day study randomization : Blood transfusion . Active alcohol drug abuse sufficient , investigator 's opinion , prevent adequate compliance study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1992</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Zidovudine</keyword>
</DOC>